@massnardone

PhD | CardioRenal

 Toronto, Ontario
Joined August 2016
  • Tweets342
  • Following627
  • Followers454
11Media
Massimo Nardone retweeted
Hypertension@HyperAHAJan 27
RESEARCH ARTICLE: Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial @massnardone @DSchnekenB ahajrnls.org/4rhIcAj
7
24
1,453
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? - The Lancet thelancet.com/journals/lance…
1
67
Beyond a singular focus on #GLP-1: why we need a new nomenclature now thelancet.com/journals/landi… multihormone receptor modulator (#MHRM)
1
8
31
2,236
Massimo Nardone retweeted
Hypertension@HyperAHA30 Jun 2025
RESEARCH ARTICLE: Establishing Reference Values for Pulse Wave Velocity in Young People: The Youth Vascular Consortium @RachelClimie @VimarshaHK @ProfRuanKruger @JeanneHersant @rosam_bruno @seanagall @alta_schutte @HanssenHenner @pierreboutouyr1 ahajrnls.org/3TihjgR
14
3
25
1,812
Research Article by @AndrLTeixeira3 et al. (@Millar_Lab @DrBurr @massnardone @JorB_L @uofg) Interindividual variability in #renal and #muscle #sympatheticresponses to #mentalstress: contributions to #bloodpressure regulation ow.ly/21BK50WeP85
1
6
24
2,558
These hard-working @UofG_HHNS authors are bringing us new #exercise research in this #ArticleinPress, Evidence for potentiation in sympathetic neurovascular transduction following exercise in normotensive adults (Massimo Nardone et al.): ow.ly/5qY350Wh47T
4
8
333
Massimo Nardone retweeted
NEJM
@NEJM22 Jun 2025
Presented at #ADASciSessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity. Full trial results: nej.md/444aW7f @ADA_DiabetesPro
2
39
4
91
29,815
Short Report by SE Hilton et al. (@massnardone @julianbommarito @Millar_Lab @uofg) Influence of #sex and #aerobicfitness on #bloodpressure during #maximal #treadmill #exercise in young healthy adults 🏃‍➡️ ow.ly/QhGU50VX2ef
1
5
18
2,737
Massimo Nardone retweeted
Philip Millar@Millar_Lab23 May 2025
Happy to share our new paper in @japplphysiol examining muscle sympathetic action potential firing after acute cannabis use pubmed.ncbi.nlm.nih.gov/4038…

Inhibition of muscle sympathetic action potential firing and recruitment patterns following...

Cannabis is among the most widely used recreational substances, but the physiological consequences of acute and chronic use remain poorly studied. We recently demonstrated that acute cannabis use...

pubmed.ncbi.nlm.nih.gov
1
4
28
998
That's a wrap! Thanks to everyone who joined us for our Annual Scientific Day at The Old Mill. Such a wonderful opportunity to network and learn.
2
8
356
Cardiovascular disease in chronic kidney disease CVD and CKD has a major impact on the prognosis of patients inflammation, anaemia, volume overload, and the presence of uraemic toxins : involvement of several pathophysiological mechanisms academic.oup.com/eurheartj/a…
23
47
2,845
Massimo Nardone retweeted
UHN Research@UHN_Research9 Apr 2025
New research from @TGHRI_UHN suggests #diabetes drugs dapagliflozin & empagliflozin may lower heart disease & kidney failure risk in people with #Type1Diabetes. Findings highlight the need for trials to confirm benefits ➡️ uhnresearch.ca/news/evaluati… #DiabetesResearch
Flatlay image with a clipboard holding a blood sugar tracker document, blood testing devices, a plastic heart-shaped figure, and a stethoscope.

ALT Flatlay image with a clipboard holding a blood sugar tracker document, blood testing devices, a plastic heart-shaped figure, and a stethoscope.

1
6
333
Dapagliflozin improves estimated CVD and ESKD risk in T1D participants, emphasizing the need for cardiorenal outcome trials in people living with T1D. bit.ly/CJASN0641 @DrValRac @FrederikPersson #ASNCJASN
1
44
1
95
5,684
Massimo Nardone retweeted
NDT@NDTsocial21 Feb 2025
Upcoming drug targets for kidney protective effects in chronic kidney disease 🆓doi.org/10.1093/ndt/gfae216
53
114
6,031
Excited to share our contributions to a special supplement on combination therapy in chronic kidney disease @NDTsocial: Upcoming drug targets for kidney protective effects in chronic kidney disease academic.oup.com/ndt/article…

Upcoming drug targets for kidney protective effects in chronic kidney disease

PLAIN ENGLISH SUMMARY . People with chronic kidney disease (CKD) are at a high risk of heart disease and end-stage kidney disease. This review describes ho

academic.oup.com
9
26
1,732
Check out our new series of reviews on CKD combination therapy in @NDTsocial academic.oup.com/ndt/issue/4…
1
11
53
2,954
Massimo Nardone retweeted
Circ: Heart Failure@CircHF12 Dec 2024
In HFpEF muscle SNS outflow is elevated during rest and exercise, compared to comorbid controls, and relates inversely to exercise capacity #AHAJournals @markbadrov @FlorasLab @massnardone ahajrnls.org/3OP9ZXU
2
9
1,207
Massimo Nardone retweeted
NDT@NDTsocial11 Dec 2024
🧐Selected from our joint @ERAkidney and @escardio Cardio-Kidney Collection: academic.oup.com/ndt/pages/j… ➡️Proximal versus distal diuretics in congestive heart failure 🔓doi.org/10.1093/ndt/gfae058
18
51
3,345
Massimo Nardone retweeted
NDT@NDTsocial11 Oct 2024
♥️ Check out our new joint ERA and ESC Cardio-Kidney Collection♥️ 👌This collection of articles from NDT/CKJ & the ESC journals sheds light on the critical importance of addressing the intertwined nature of cardiovascular, kidney & metabolic disorders academic.oup.com/ndt/pages/j…
1
19
67
4,338
Massimo Nardone retweeted
UHN Research@UHN_Research16 Sep 2024
Replying to @UHN_Research @UHN
#PostdocAppreciationWeek 👋Meet Massimo (@massnardone), a Postdoctoral Researcher @UHN’s @TGHRI_UHN. Read about his research and what he thinks about the future of health research! > uhnresearch.ca/news/massimo-…
Smiling male researcher with text quotation overlay.

ALT Smiling male researcher with text quotation overlay.

1
3
11
708
Load more